Celgene to give oral presentations on beta-thalassemia.

, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for malignancy and rare diseases, today reported that Acceleron, Celgene and investigators in the sotatercept and ACE-536 phase 2 medical trials gives three oral presentations of interim data from ongoing studies in beta-thalassemia and myelodysplastic syndromes in addition to a poster presentation of non-clinical data in sickle cell disease at the 19th Annual Congress of the European Hematology Association in Milan, Italy from June 12-15, 2014. ACE-536: Beta-thalassemia Oral Display ACE-536: Myelodysplastic Syndromes Oral Demonstration Sotatercept: Beta-thalassemia Oral Display ACE-536: Sickle Cell Disease Poster Presentation..Through the first one fourth of 2011, Agensys submitted an investigational new medication software to the U.S. Food and Medication Administration for a phase I trial of ASG-22ME. Seattle Genetics and Agensys are also co-developing another ADC known as ASG-5ME, which happens to be in phase I medical trials for pancreatic and prostate cancer. Related StoriesRUCDR Infinite Biologics awarded $6 million grant from NINDSGenetics and race influence individuals' response to anticancer drug treatmentsBrodalumab therapy achieves 100 percent decrease in psoriasis symptoms ASG-22ME is the second ADC we are co-developing under our collaboration with Agensys/Astellas, and the fifteenth ADC using Seattle Genetics’ technology in clinical advancement across both our internal pipeline and collaborator applications, stated Eric L.